• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Channel Therapeutics Corporation

    11/22/24 4:33:04 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRO alert in real time by email
    POS AM 1 g084565_s1.htm POS AM

    As filed with the U.S. Securities and Exchange Commission on November 22, 2024

     

    Registration No. 333-281070

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-1

     

    REGISTRATION STATEMENT

    UNDER THE

    SECURITIES ACT OF 1933

     

    Channel Therapeutics Corporation 

    (Exact name of registrant as specified in its charter)

     

    Nevada   2836   86-3335449
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification Number)

     

    Channel Therapeutics Corporation

    4400 Route 9 South, Suite 1000

    Freehold, NJ 07728

    (877)-265-8266 

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Francis Knuettel II

    Chief Executive Officer and
    Chief Financial Officer, President, Treasurer and Secretary

    4400 Route 9 South, Suite 1000
    Freehold, NJ 07728

    Tel. No.: 732-514-2636

     

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    David E. Danovitch, Esq.

    Charles E. Chambers Jr., Esq.

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, NY 10020

    (212) 660-3060

     

    Approximate date of commencement of proposed sale to the public: Not applicable.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

    EXPLANATORY NOTE

     

    On November 18, 2024 (the “Effective Time”), Chromocell Therapeutics Corporation, a Delaware corporation (the “Predecessor Registrant”), merged with and into its wholly-owned subsidiary, Channel Therapeutics Corporation, a Nevada corporation (the “Registrant”), pursuant to an agreement and plan of merger, dated as of November 18, 2024 (the “Agreement”), between the Predecessor Registrant and the Registrant, with the Registrant as the surviving corporation (such transaction, the “Reincorporation”). At the Effective Time, the Registrant succeeded to the assets, continued the business and assumed the rights and obligations of the Predecessor Registrant existing immediately prior to the Reincorporation. The Reincorporation was consummated by the filing of a certificate of ownership and merger on November 18, 2024 with the Secretary of State of the State of Delaware (the “Delaware Certificate”) and the articles of merger with the Secretary of State of the State of Nevada (the “Nevada Articles”). The Agreement and transactions contemplated thereby were approved by the affirmative vote of a majority of the outstanding shares of the Predecessor Registrant’s common stock, par value $0.0001 per share (the “Predecessor Common Stock”), and entitled to vote on the matter, at the Predecessor Registrant’s Annual Meeting of Stockholders held on October 22, 2024, in accordance with the General Corporation Law of the State of Delaware (“DGCL”).

     

    At the Effective Time, pursuant to the Agreement, (i) each outstanding share of the Predecessor Common Stock automatically converted into one share of common stock, par value $0.0001 per share, of the Registrant (“Registrant Common Stock”), (ii) each outstanding share of the Series C Convertible Redeemable Preferred Stock of the Company, par value $0.0001 per share (the “Predecessor Series C Preferred Stock”) automatically converted into one share of Series C Convertible Redeemable Preferred Stock, par value $0.0001 per share, of the Registrant (“Registrant Series C Preferred Stock”), (iii) each outstanding option, right or warrant to acquire shares of Predecessor Common Stock converted into an option, right or warrant, as applicable, to acquire an equal number of shares of Registrant Common Stock under the same terms and conditions as the original options, rights or warrants, as applicable, and (iv) the directors and executive officers of the Predecessor Registrant were appointed as directors and executive officers, as applicable, of the Registrant, each to serve in the same capacity and for the same term as such person served with the Predecessor Registrant immediately prior to the Reincorporation. In addition, by operation of law, the Registrant assumed all of the Predecessor Registrant’s obligations under its equity incentive plans and employment agreements. The shares of Predecessor Common Stock remaining available for awards under such plans were automatically adjusted upon the Reincorporation into an identical number of shares of Registrant Common Stock, and all awards previously granted under such plans that were outstanding as of the Effective Time were automatically adjusted into awards for the identical number of shares of Registrant Common Stock, without any other change to the form, terms or conditions of such awards.

     

    As a result of the Reincorporation, the Registrant ceased to be subject to the DGCL or governed by the Predecessor Registrant’s amended and restated certificate of incorporation (the “Delaware Charter”) and its amended and restated by-laws (the “Delaware Bylaws”). As of the Effective Time, the Registrant became subject to the Nevada Revised Statutes of the State of Nevada (“NRS”) and became governed by the Registrant’s articles of incorporation (the “Nevada Charter”) and bylaws (the “Nevada Bylaws”). The Registrant Series C Preferred Stock became governed by the Nevada Charter and the Nevada Bylaws, as well as the Registrant’s Certificate of Designations of Series C Convertible Redeemable Preferred Stock (the “Registrant Series C CoD”).

     

    At the Effective Time, the Registrant became the successor issuer to the Predecessor Registrant pursuant to Rule 12g-3(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As the successor issuer, the Registrant Common Stock, as a class of capital stock of the Registrant, is deemed to be registered under Section 12(b) of the Exchange Act and the Registrant succeeded to the Predecessor Registrant’s obligation to file reports, proxy statements and other information required by the Exchange Act with the U.S. Securities and Exchange Commission (the “Commission”).

     

    The Registrant Common Stock is listed on the NYSE American LLC under the symbol “CHRO,” which is the same symbol previously used for the Predecessor Common Stock. In accordance with the Agreement, each outstanding certificate previously representing shares of Predecessor Common Stock or Predecessor Series C Preferred Stock automatically represents, without any action of the Predecessor Registrant’s stockholders, the same number of shares of Registrant Common Stock or Registrant Series C Preferred Stock, as applicable.

     

     

    In connection with the Reincorporation, on November 18, 2024, the Registrant entered into updated indemnification agreements with each of its directors and executive officers, reflecting the transition from Delaware to Nevada. Such indemnification agreements require the Registrant to indemnify the Registrant’s directors and executive officers, as applicable, to the fullest extent permitted by Nevada law. A copy of the form of such indemnification agreement is filed as an exhibit to Registrant’s Current Report on Form 8-K filed with the Commission on November 18, 2024 (the “Form 8-K”).

     

    The Registrant is filing this post-effective amendment No. 1 (this “Post-Effective Amendment”) to the Registration Statement on Form S-1 (File No. 333-281070), as amended (the “Registration Statement”), initially filed with the Commission on July 29, 2024 and declared effective by the Commission on August 6, 2024, in connection with the Reincorporation. In accordance with Rule 414(d) under the Securities Act of 1933, as amended (the “Securities Act”), except as modified by this Post-Effective Amendment, the Registrant, now as successor issuer to the Predecessor Registrant pursuant to Rule 12g-3 of the Exchange Act, hereby expressly adopts the Registration Statement as its own registration statement for all purposes of the Securities Act and the Exchange Act, including the prospectuses included therein.

     

    For the purposes of this Post-Effective Amendment and the Registration Statement, unless the context otherwise requires, the term “our,” or “us” refers to the Predecessor Registrant and its subsidiaries, as applicable, with respect to the period prior to the Effective Time and to the Registrant with respect to the period on and after the Effective Time.

     

    The prospectus contained in the Registration Statement incorporates by reference all documents filed by the Predecessor Registrant under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial filing of the Registration Statement and will incorporate by reference all documents filed by the Registrant under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act following the date of this Post-Effective Amendment. The prospectus contained in the Registration Statement, as well as all documents filed by us under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act before the Effective Time and incorporated by reference in the Registration Statement, will not reflect any change in our name or capital stock, among other things. With respect to such information, or any other information contained or incorporated by reference in the Registration Statement that is modified by information subsequently incorporated by reference in the Registration Statement, the statement or information previously contained or incorporated in the Registration Statement shall also be deemed modified or superseded in the same manner.

     

    The rights of the holders of Registrant Common Stock are now governed by the Nevada Charter and the Nevada Bylaws, each of which is filed as an exhibit to the Form 8-K, and the rights of the holders of Registrant Series C Preferred Stock are now governed by the Nevada Charter and the Nevada Bylaws, as well as the Registrant Series C CoD, which is filed as an exhibit to the Form 8-K.

     

    The Registration Statement and prospectuses forming a part thereof shall remain unchanged in all other respects. Accordingly, this Post-Effective Amendment consists only of this explanatory note and revised versions of certain exhibits to replace and/or supplement certain exhibits on the exhibit index filed with the Registration Statement, which revised exhibits are filed with this Post-Effective Amendment. No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the Registration Statement.

     

     

     PART II - INFORMATION NOT REQUIRED IN THE PROSPECTUS

     

    Item 14. Indemnification of Officers and Directors.

     

    Set forth below is a description of certain provisions of the registrant’s (the “Registrant” or “Company”) articles of incorporation (the “Articles of Incorporation”), and bylaws (the “Bylaws”) and the Nevada Revised Statutes (the “NRS”), as such provisions relate to the indemnification of the directors and officers of the Registrant, as well as the Registrant’s agreements with certain of its officers and directors. This description is intended only as a summary and is qualified in its entirety by reference to the Articles of Incorporation, the Bylaws, the NRS and such agreements described below.

     

    The Registrant is incorporated under the laws of the State of Nevada. Section 78.138 of the NRS provides that, subject to certain exceptions under Nevada law, unless the articles of incorporation or an amendment thereto provides for greater individual liability, a director or officer is not individually liable to the Registrant or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven that (i) the director’s or officer’s act or failure to act constituted a breach of his or her fiduciary duties as a director or officer and (ii) the breach of those duties involved intentional misconduct, fraud or a knowing violation of law. The Articles of Incorporation further provide that the personal liability of the directors of the Registrant is eliminated to the fullest extent permitted by the NRS.

     

    Section 78.7502 of the NRS provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action, suit or proceeding if the person acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the conduct was unlawful.

     

    NRS Section 78.7502 also provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by the person in connection with the defense or settlement of the action or suit if the person acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation; provided, however, that indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

     

    Any indemnification pursuant to the above provisions may be made by the corporation only as authorized in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances. The determination must be made: (a) by the stockholders; (b) by the board of directors by majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding; (c) if a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion; or (d) if a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion. The Registrant’s Articles of Incorporation and Bylaws comply with Nevada law as set forth above.

     

     

    As permitted by Section 78.138 of the NRS, Article VII of the Articles of Incorporation provides:

     

    “To the full extent permitted by the Act and any other applicable law currently or hereafter in effect, no director or officer of the Company will be personally liable to the Company or its stockholders for or with respect to any breach of fiduciary duty or other act or omission as a director.”

     

    The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any bylaw provision, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such person.

     

    The Registrant has entered into indemnification agreements with each of its directors and executive officers, pursuant to which the Registrant has agreed to indemnify such persons against all expenses and liabilities incurred or paid by such persons in connection with any proceeding arising from the fact that such persons are or were officers or directors of the Registrant, and to advance expenses as incurred by or on behalf of such persons in connection therewith.

     

    In addition, in connection with the Registrant’s reincorporation from the State of Delaware to the State of Nevada effective as of November 18, 2024, the Registrant intends to continue to maintain general liability insurance policy that covers liabilities of its directors and officers arising out of claims based on acts or omissions in their respective capacities as such directors or officers.

     

    See “Item 17. Undertakings” of the Registration Statement for a description of the Commission’s position regarding such indemnification provisions.

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description of Exhibit
    2.2   Agreement and Plan of Merger, dated as of November 18, 2024 (1)
    2.3   Certificate of Ownership and Merger, filed with the Secretary of State of the State of Delaware on November 18, 2024 (1)
    2.4   Articles of Merger, filed with the Secretary of State of the State of Nevada on November 18, 2024 (1)
    3.1(i)(a)   Articles of Incorporation, filed with the Secretary of State of the State of Nevada on November 5, 2024 (1)
    3.1(i)(b)   Certificate of Correction to Articles of Incorporation, filed with the Secretary of State of the State of Nevada on November 7, 2024 (1)
    3.1(i)(c)   Certificate of Designations of Series C Convertible Redeemable Preferred Stock, filed with the Secretary of State of the State of Nevada on November 8, 2024 (1)
    3.1(ii)   Bylaws (1)
    10.20†   Form of Indemnification Agreement (1)
    5.2*   Opinion of Sullivan & Worcester LLP
    23.3*   Consent of Marcum LLP
    23.5*   Consent of Sullivan & Worcester LLP (included in Exhibit 5.2)

     

    * Filed herewith.

    † Management contract or compensatory plan or arrangement.

     

      (1) Filed as an exhibit to the Company’s Current Report on Form 8-K, filed with the Commission on November 18, 2024.

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Post-Effective Amendment No. 1 to Form S-1 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in North Brunswick, State of New Jersey, on November 22, 2024.

     

      CHANNEL THERAPEUTICS CORPORATION
         
      By: /s/ Francis Knuettel II
        Francis Knuettel II
        Chief Executive Officer and President, Chief Financial Officer, Treasurer and Secretary (Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer)

     

    Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to Form S-1 Registration Statement has been signed by the following persons in the capacities and on the dates stated.

     

    Signature   Title   Date
             
    *   Chief Executive Officer and President, Chief Financial Officer, Treasurer, Secretary and Director   November 22, 2024
    Francis Knuettel II        
             
    *   Director   November 22, 2024
    Ezra Friedberg        
             
    *   Director   November 22, 2024
    Todd Davis        
             
    *   Director   November 22, 2024
    Richard Malamut        
             
    *   Director   November 22, 2024
    Chia-Lin Simmons        

     

    * By: /s/ Francis Knuettel II  
    Name:  Francis Knuettel II  
      Attorney-in-fact  

     

    Get the next $CHRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHRO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Malamut Richard bought $9,825 worth of shares (10,400 units at $0.94) (SEC Form 4)

    4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

    9/16/24 4:56:55 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $5,044 worth of shares (5,200 units at $0.97) (SEC Form 4)

    4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

    9/16/24 4:55:23 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO, Pres., CFO, Treas & Secty Francis Knuettel Ii bought $10,955 worth of shares (12,000 units at $0.91) (SEC Form 4)

    4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

    9/12/24 5:35:41 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Baxter Richard B

    4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

    7/7/25 9:47:34 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Greenleaf Peter

    4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

    7/7/25 9:46:35 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Pauls Matthew

    4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

    7/7/25 9:45:34 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

    ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the goMolluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for high un

    7/10/25 8:00:00 AM ET
    $CHRO
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

    The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

    7/2/25 7:00:00 AM ET
    $CHRO
    $LGND
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

    FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Reverse Stock Split is intended to increase the market price per share of the Company's Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the "NYSE American") in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and in

    6/27/25 9:15:00 AM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRO
    SEC Filings

    View All

    SEC Form D filed by Channel Therapeutics Corporation

    D - Pelthos Therapeutics Inc. (0001919246) (Filer)

    7/10/25 4:15:20 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Channel Therapeutics Corporation

    SCHEDULE 13G - Pelthos Therapeutics Inc. (0001919246) (Subject)

    7/8/25 4:05:35 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Channel Therapeutics Corporation

    SCHEDULE 13D/A - Pelthos Therapeutics Inc. (0001919246) (Subject)

    7/3/25 9:07:22 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRO
    Leadership Updates

    Live Leadership Updates

    View All

    Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

    The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

    7/2/25 7:00:00 AM ET
    $CHRO
    $LGND
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CHRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Chromocell Therapeutics Corporation

    SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)

    11/13/24 4:05:24 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Chromocell Therapeutics Corporation

    SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

    3/4/24 4:07:02 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Chromocell Therapeutics Corporation

    SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

    3/1/24 5:19:37 PM ET
    $CHRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care